Dyadic International Inc (NASDAQ:DYAI) — Market Cap & Net Worth
Market Cap & Net Worth: Dyadic International Inc (DYAI)
Dyadic International Inc (NASDAQ:DYAI) has a market capitalization of $30.71 Million ($30.71 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23740 globally and #5080 in its home market, demonstrating a 25.64% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dyadic International Inc's stock price $0.85 by its total outstanding shares 36187798 (36.19 Million). Review DYAI liabilities breakdown to assess the company's total debt and financial obligations.
Dyadic International Inc Market Cap History: 2015 to 2026
Dyadic International Inc's market capitalization history from 2015 to 2026. Data shows change from $65.50 Million to $30.71 Million (-1.25% CAGR).
Index Memberships
Dyadic International Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #683 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2253 of 3165 |
Weight: Dyadic International Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dyadic International Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dyadic International Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
18.12x
Dyadic International Inc's market cap is 18.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $65.50 Million | $315.71K | $65.79 Million | 207.47x | 1.00x |
| 2016 | $60.07 Million | $592.89K | -$3.61 Million | 101.32x | N/A |
| 2017 | $50.30 Million | $758.42K | -$2.14 Million | 66.32x | N/A |
| 2018 | $68.39 Million | $1.30 Million | -$5.69 Million | 52.80x | N/A |
| 2019 | $187.45 Million | $1.68 Million | -$8.31 Million | 111.51x | N/A |
| 2020 | $194.69 Million | $1.60 Million | -$9.33 Million | 121.54x | N/A |
| 2021 | $163.57 Million | $2.40 Million | -$13.07 Million | 68.05x | N/A |
| 2022 | $44.51 Million | $2.93 Million | -$9.74 Million | 15.19x | N/A |
| 2023 | $58.26 Million | $2.90 Million | -$6.80 Million | 20.10x | N/A |
| 2024 | $63.33 Million | $3.50 Million | -$5.81 Million | 18.12x | N/A |
Competitor Companies of DYAI by Market Capitalization
Companies near Dyadic International Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Dyadic International Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Dyadic International Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Dyadic International Inc's market cap moved from $65.50 Million to $ 30.71 Million, with a yearly change of -1.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $30.71 Million | -9.72% |
| 2025 | $34.02 Million | -46.29% |
| 2024 | $63.33 Million | +8.70% |
| 2023 | $58.26 Million | +30.89% |
| 2022 | $44.51 Million | -72.79% |
| 2021 | $163.57 Million | -15.99% |
| 2020 | $194.69 Million | +3.86% |
| 2019 | $187.45 Million | +174.07% |
| 2018 | $68.39 Million | +35.97% |
| 2017 | $50.30 Million | -16.27% |
| 2016 | $60.07 Million | -8.29% |
| 2015 | $65.50 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Dyadic International Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.71 Million USD |
| MoneyControl | $30.71 Million USD |
| MarketWatch | $30.71 Million USD |
| marketcap.company | $30.71 Million USD |
| Reuters | $30.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dyadic International Inc
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and la… Read more